All news

(Image: Getty/Radachynskyi)

Recro spins out Baudax to boost CDMO focus

By Vassia Barba

Recro Pharma announces the separation of its acute care business to launch Baudax Bio as a developer of products, including non-opioid analgesics, to concentrate on its CDMO business.

(Image: Getty/chombosan)

FT PHARMACEUTICAL & BIOTECHNOLOGY CONFERENCE

The danger of ‘going too far’ with AI

By Vassia Barba

Industry experts dealing with AI services should be showing both devotion to the possibilities opened and skepticism at the same time, says ICON exec.

Follow us

Products

View more

Webinars